The COVID-19 Crisis

Update October 28, 2021
CAVEAT!
I am not THAT kind of doctor.
I study rocks.

Ariel D. Anbar
Professor
School of Earth and Space Exploration
School of Molecular Sciences
Arizona State University
Dunning–Kruger Effect

- Peak of "Mount Ignorance"
  - FACEBOOK 'EXPERT'
- Plateau of Sustainability
  - SCIENTISTS
  - DOCTOR

Confidence

Know nothing

Competence

Guru

Slope of Enlightenment

Valley of Despair
The stacked bar chart colors represent the proportion of SARS-CoV-2 variants circulating in Arizona by week. Data of COVID-19 cases are genetically sequenced to monitor variant distribution. Source: Efrem Lim, Biodesign Center for Fundamental and Applied Microbiomics and other laboratories who obtained samples, generated data share via GISAID and NCBI.
Hospital Bed Capacity

Number of Inpatient Beds ■ Available, ■ In Use by non-COVID Patients, and ■ In Use by COVID Patients (starting 4/10/20) at Arizona Hospitals

Number of Intensive Care Unit (ICU) Beds ■ Available, ■ In Use by non-COVID Patients, and ■ In Use by COVID Patients (starting 4/10/20) at Arizona Hospitals
Rates for vaccinated and unvaccinated

Data from the Centers for Disease Control and Prevention shows that people who are unvaccinated are at a much greater risk than those who are fully vaccinated to get sick or die from Covid-19. These charts compare average daily case and death rates for vaccinated and unvaccinated people in the 14 states and two cities that provide this data.

Average daily cases
100 cases per 100,000

Average daily deaths
1.5 deaths per 100,000

About this data:
Source: Centers for Disease Control and Prevention. This data was made available on Oct. 15, 2021, and is expected to update monthly. The C.D.C. releases the data as a weekly figure per 100,000 and is presented as a daily average per 100,000 for consistency with other population-adjusted figures on this page. See the notes on the C.D.C.'s page for more information.

Waning Immunity after the BNT162b2 Vaccine in Israel

A SARS-CoV-2 Infection

Full Vaccination Period
(time before study period)

- Before vaccine was available for the age group
- January 16–31 (approx. 6 mo)
- February 1–15 (approx. 5.5 mo)
- February 16–28 (approx. 5 mo)
- March 1–15 (approx. 4.5 mo)
- March 16–31 (approx. 4 mo)
- April (approx. 3 mo)
- May (approx. 2 mo)

N ~ 5 million people
KOLD FACT FINDERS

EXPERTS DIVIDED ON BOOSTER BENEFITS

SOME SAY GETTING OTHER COUNTRIES VACCINATED SHOULD BE PRIORITY
Waning Immunity after the BNT162b2 Vaccine in Israel

October 27, 2021
DOI: 10.1056/NEJMo2114228

B Severe Covid-19

Full Vaccination Period
(time before study period)

- □ Before vaccine was available for the age group
- ■ January (approx. 6 mo)
- □ February (approx. 5 mo)
- † March (approx. 4 mo)
- □ April–May (approx. 2–3 mo)

Severe Covid-19 Rate during Study Period
(per 1000 persons)

Age Group (yr)

16–39
40–59
≥60

N ~ 5 million people
Figure 2. Reduction in Rate of Confirmed Infection in Booster Group as Compared with Nonbooster Group.

N ~ 1 million people
Age = > 60 years
KEEP CALM AND CARRY ON